Glucose B. Braun

Glucose B. Braun is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. The product is supplied in an aqueous solution, with the concentration not disclosed, and is marketed in the European Union. It is classified as an excipient/solvent used in parenteral nutrition and is available by prescription only. It is for use under supervision to provide carbohydrate calories and fluid support during IV therapy.

Glucose B. Braun is employed in clinical settings where intravenous carbohydrate and fluid replacement are required.

- Management of hypoglycemia when oral intake is not possible. - Component of total parenteral nutrition formulations to supply energy. - Fluid and electrolyte replacement in patients unable to tolerate oral fluids. - Support during perioperative periods where fasting is mandated. - Adjunct in pediatric or neonatal care for caloric supplementation. - Use as a diluent for compatible intravenous medications requiring a carbohydrate carrier.

When administered intravenously, Glucose B. Braun may be associated with a range of observed effects, most of which are related to its glucose content and fluid volume.

Common: - Transient rise in blood glucose levels. - Mild hyperosmolarity leading to temporary thirst. - Local irritation at the infusion site if solution is not properly diluted. - Electrolyte shifts such as mild hyponatremia due to fluid load. - Mild nausea or abdominal discomfort. - Temporary increase in urine output due to osmotic diuresis.

Serious: - Severe hyperglycemia, especially in patients with diabetes mellitus. - Fluid overload resulting in pulmonary edema. - Hyperosmolar hyperglycemic state (HHS) in susceptible individuals. - Acute metabolic acidosis in patients with impaired renal function.

Glucose B. Braun should be administered with attention to patient-specific factors and clinical conditions to minimize risks.

- Verify blood glucose levels before and during infusion, especially in diabetic patients. - Adjust infusion rate in individuals at risk for fluid overload, such as those with heart or renal failure. - Use aseptic technique to prevent contamination of the intravenous solution. - Monitor electrolytes, particularly sodium and potassium, as shifts may occur with large volumes. - Avoid rapid infusion in neonates and infants to prevent hyperglycemia. - Consider compatibility with other IV drugs; incompatibility may cause precipitation. - Document any adverse reactions promptly in the patient record.

Glucose B. Braun may interact with other intravenous agents or systemic medications, influencing glucose homeostasis or fluid balance.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate monitoring. - Simultaneous infusion of hypertonic saline solutions that could exacerbate hyperosmolarity. - Mixing with calcium‑containing solutions that may precipitate.

Use with caution: - Concurrent use of diuretics, which may amplify fluid shifts. - Administration alongside oral hypoglycemic agents; blood glucose should be closely observed. - Use in patients receiving total parenteral nutrition containing other carbohydrate sources to avoid excess caloric load. - Caution when combined with vasopressors, as rapid volume changes may affect hemodynamics.